PDCD1 and non-small cell lung carcinoma: Currently, the monoclonal anti-PD-1/PD-L1 antibodies that were approved by the US FDA to treat advanced NSCLC include nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab (168).